Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathy Miller

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Breast Cancer Research and Treatment|February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew Wardley, Javier Cortes, Louise Provencher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
American Heart Journal|June 19, 2018
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) TrialRoberto Bolli, Joshua M Hare, Timothy D Henry, et al.
Mabs|March 2, 2010
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2Roni Mamluk, Irvith M Carvajal, Brent A Morse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid TumorsTinya Abrams, Anu Connor, Christie Fanton, et al.
Molecular Cancer Therapeutics|April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing MalignanciesQing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
The New England Journal of Medicine|January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast CancerOtto Metzger, Sumithra Mandrekar, Shom Goel, et al.
JACC. Cardiooncology|January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA TrialRoberto Bolli, Emerson C Perin, James T Willerson, et al.
Nature|December 11, 2012
Seventy-five genetic loci influencing the human red blood cellPim van der Harst, Weihua Zhang, Irene Mateo Leach, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Breast Cancer Research and Treatment|February 16, 2021
The efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew Wardley, Javier Cortes, Louise Provencher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2025
Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II studyLorenzo Gerratana, Carolina Reduzzi, Yue Ren, et al.
American Heart Journal|June 19, 2018
Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) TrialRoberto Bolli, Joshua M Hare, Timothy D Henry, et al.
Mabs|March 2, 2010
Anti-tumor effect of CT-322 as an adnectin inhibitor of vascular endothelial growth factor receptor-2Roni Mamluk, Irvith M Carvajal, Brent A Morse, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 17, 2018
Preclinical Antitumor Activity of a Novel Anti-c-KIT Antibody-Drug Conjugate against Mutant and Wild-type c-KIT-Positive Solid TumorsTinya Abrams, Anu Connor, Christie Fanton, et al.
Molecular Cancer Therapeutics|April 21, 2021
PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing MalignanciesQing Sheng, Joseph A D'Alessio, Daniel L Menezes, et al.
The New England Journal of Medicine|January 28, 2026
Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast CancerOtto Metzger, Sumithra Mandrekar, Shom Goel, et al.
JACC. Cardiooncology|January 6, 2021
Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA TrialRoberto Bolli, Emerson C Perin, James T Willerson, et al.
Nature|December 11, 2012
Seventy-five genetic loci influencing the human red blood cellPim van der Harst, Weihua Zhang, Irene Mateo Leach, et al.
Pageof 5